Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy

Table 7 Correlation of clinical responses and plasma concentrations of 5-AZA-CdR in patients with MDS

Dose-schedule	Duration of infusion	Estimated plasma concentration	Response % ORR (%CR)	References
20 mg/m²/day i.v. q 5d	1hour	1.25 μM	34 (33)	[99]
10 mg/m²/day i.v. q 10d	1hour	0.63 μM
15 mg/m² i.v t.i.d. x 3d	4 hours	0.23 μM	20(15)	[123]
15 mg/m² t.i.d. q3d	3 hours	0.31 μM	17 (9)	[105]

1 μM = 228 ng/ml. 5-AZA-CdR, 5-aza-2′-deoxycytidine; CR, complete remission; MDS, myelodysplastic syndrome; ORR, overall response rate.

ISSN: 1868-7083